HealthiNation Wins Gold at 2017 International Davey Awards

NEW YORK, Dec. 13, 2017 (GLOBE NEWSWIRE) -- HealthiNation, a leading producer and publisher of original health, food and fitness videos was selected as a 2017 Gold Award Winner at the 13th Annual International Davey Awards in the Online Film/Video category for its heart-healthy cooking series, Dr. Mike Cooks.  The featured episode of this five-part (six-minute each), … [Read more...]

NetworkNewsWire Announces Publication Discussing the Production of Quality Cannabinoids with Therapeutic Potential

NEW YORK, Dec. 13, 2017 (GLOBE NEWSWIRE) -- via NetworkNewsWire - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE:IN) (OTCQB:IMLFF), a client of NNW and a preclinical stage biopharmaceutical company specializing in the research and development of novel, … [Read more...]

Michael T. Redman, Chairman of the Board and CEO of Oncolix, Inc., Provides Progress Report and Outlook for Investors in New Audio Interview at SmallCapVoice.com

AUSTIN, Texas, Dec. 13, 2017 (GLOBE NEWSWIRE) -- SmallCapVoice.com, Inc. (SCV) and Oncolix, Inc. (“The Company”) (OTC:ONCX), a biotechnology company focused on gynecological cancers, today announced that a new audio interview with the Company is now available. The interview can be heard at https://smallcapvoice.com/blog/12-1-17-smallcapvoice-interview-with-oncolix-inc-oncx … [Read more...]

Clementia lance l’essai clinique pivot de phase 3 MOVE sur le palovarotene chez les patients atteints de fibrodysplasie ossifiante progressive

L’administration de palovarotene aux patients a débuté; quatre-vingts patients du monde entier seront inscrits à l’étude d’homologation La société tiendra une conférence téléphonique à 8 h 30 HNE aujourd’hui MONTRÉAL, 12 déc. 2017 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ : CMTA), une société biopharmaceutique au stade clinique proposant des … [Read more...]

Fibrocell Announces Closing of $10.5 Million Underwritten Public Offering

EXTON, Pa., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC), a gene therapy company focused on transformational autologous cell-based therapies for skin and connective tissue diseases, today announced the closing of the previously announced underwritten public offering of 13,636,364 shares of its common stock (Common Stock) (or Common Stock equivalent) … [Read more...]